Bharat Serums And Vaccines Profile
Key Indicators
- Authorised Capital ₹ 352.16 Cr
- Paid Up Capital ₹ 7.31 M
- Company Age 31 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 466.00 Cr
- Satisfied Charges ₹ 65.00 Cr
- Revenue Growth 31.84%
- Profit Growth 44.88%
- Ebitda 62.12%
- Net Worth 2.93%
- Total Assets -9.78%
About Bharat Serums And Vaccines
Bharat Serums And Vaccines Limited (BSAVL) is a leading Public Limited Indian Non-Government Company incorporated in India on 11 November 1993 and has a history of 31 years and three months. Its registered office is in Thane, Maharashtra, India.
The Corporate was formerly known as Aksipro Diagnostics P Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 352.16 Cr and a paid-up capital of Rs 7.31 M.
The company currently has active open charges totaling ₹466.00 Cr. The company has closed loans amounting to ₹65.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Bharat Serums And Vaccines Limited India are Anupama Pai as COMPANY SECRETARY and Chirag Mehta as Cfo. Surendra Lunia, Rajeev Juneja, Sheetal Arora, and Two other members serve as directors at the Company.
Company Details
- Location
Thane, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U74110MH1993PLC075088
- Company No.
075088
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
11 Nov 1993
- Date of AGM
12 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Bharat Serums And Vaccines?
Executive Team (3)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Sanjiv Navangul ![]() | Managing Director | 06-Feb-2020 | Current |
Anupama Pai ![]() | Company Secretary | 22-Sep-2021 | Current |
Chirag Mehta ![]() | CFO | 22-Sep-2021 | Current |
Board Members (4)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Surendra Lunia ![]() | Additional Director | 04-Dec-2024 | Current |
Rajeev Juneja ![]() | Additional Director | 23-Oct-2024 | Current |
Sheetal Arora ![]() | Additional Director | 23-Oct-2024 | Current |
Arjun Juneja ![]() | Additional Director | 23-Oct-2024 | Current |
Financial Performance of Bharat Serums And Vaccines.
Bharat Serums And Vaccines Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 31.84% increase. The company also saw a substantial improvement in profitability, with a 44.88% increase in profit. The company's net worth moved up by a moderate rise of 2.93%.


- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Bharat Serums And Vaccines?
In 2022, Bharat Serums And Vaccines had a promoter holding of 75.10% and a public holding of 24.91%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Charges (Loans)
₹466.00 Cr
₹65.00 Cr
Charges Breakdown by Lending Institutions
- Citi Bank N.A. : 225.00 Cr
- Others : 135.00 Cr
- Axis Bank Limited : 65.00 Cr
- Idbi Bank Limited : 35.00 Cr
- Hdfc Bank Limited : 6.00 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
15 Oct 2024 | Citi Bank N.A. | ₹200.00 Cr | Open |
29 Jun 2024 | Others | ₹25.00 Cr | Open |
18 Nov 2022 | Citi Bank N.A. | ₹25.00 Cr | Open |
09 Sep 2021 | Hdfc Bank Limited | ₹6.00 Cr | Open |
20 Aug 2021 | Others | ₹85.00 Cr | Open |
How Many Employees Work at Bharat Serums And Vaccines?
Bharat Serums And Vaccines has a workforce of 1786 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Bharat Serums And Vaccines, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bharat Serums And Vaccines's trajectory.
Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.